Astrazeneca Adjunctive Gastric Cancer Treatment Study Meets Primary Endpoint

MT Newswires Live

Mar 07, 2025

Astrazeneca (AZN) said Friday that results from a phase 3 trial of Imfinzi in combination with standard-of-care chemotherapy to treat certain gastric cancers met the primary endpoint of event-free survival.

Patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers were treated with neoadjuvant Imfinzi in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.

Astrazeneca also said that for the secondary endpoint of overall survival, a "strong trend" was seen in the interim analysis that favors the Imfinzi-based regimen.

The adjunctive therapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2517633487"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517633487\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517633487?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-07 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517633487","market":"us","top_or_hot":-1,"title":"Astrazeneca Adjunctive Gastric Cancer Treatment Study Meets Primary Endpoint","media":"MT Newswires Live","content":"<html><body><p> Astrazeneca (AZN) said Friday that results from a phase 3 trial of Imfinzi in combination with standard-of-care chemotherapy to treat certain gastric cancers met the primary endpoint of event-free survival.</p><p>Patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers were treated with neoadjuvant Imfinzi in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.</p><p>Astrazeneca also said that for the secondary endpoint of overall survival, a \"strong trend\" was seen in the interim analysis that favors the Imfinzi-based regimen.</p><p>The adjunctive therapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astrazeneca Adjunctive Gastric Cancer Treatment Study Meets Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstrazeneca Adjunctive Gastric Cancer Treatment Study Meets Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-07 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Astrazeneca (AZN) said Friday that results from a phase 3 trial of Imfinzi in combination with standard-of-care chemotherapy to treat certain gastric cancers met the primary endpoint of event-free survival.</p><p>Patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers were treated with neoadjuvant Imfinzi in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.</p><p>Astrazeneca also said that for the secondary endpoint of overall survival, a \"strong trend\" was seen in the interim analysis that favors the Imfinzi-based regimen.</p><p>The adjunctive therapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2236285917.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2517633487","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517633487","pubTimestamp":1741352147,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Astrazeneca (AZN) said Friday that results from a phase 3 trial of Imfinzi in combination with standard-of-care chemotherapy to treat certain gastric cancers met the primary endpoint of event-free sur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","AZN":"阿斯利康","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4568":"美国抗疫概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4007":"制药","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1829250122.USD":"高盛欧洲核心股票组合Acc"},"translate_title":"阿斯利康胃癌辅助治疗研究达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9},"content_text":"Astrazeneca (AZN) said Friday that results from a phase 3 trial of Imfinzi in combination with standard-of-care chemotherapy to treat certain gastric cancers met the primary endpoint of event-free survival.Patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers were treated with neoadjuvant Imfinzi in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.Astrazeneca also said that for the secondary endpoint of overall survival, a \"strong trend\" was seen in the interim analysis that favors the Imfinzi-based regimen.The adjunctive therapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}